GRAIL, Inc. (NASDAQ:GRAL) Stock Has Consensus Price Target of $119.80

Key Points

• Analysts maintain a “Hold” consensus on GRAIL, with six hold, five buy and one sell rating. The average 12-month price target is $119.80, below the reported opening price of $139.91.
• GRAIL’s latest quarter exceeded expectations, reporting an adjusted loss of $2.56 per share versus estimates of $2.66 and revenue of $44.69 million versus $42.39 million. However, the company remains unprofitable, with analysts expecting a full-year loss of $10.07 per share.
• Insiders sold substantial shares: executives sold 129,944 shares worth about $14.8 million over the last quarter, including sales by the CEO and CFO. GRAIL develops Galleri, a prescription blood-based test designed for early detection of multiple cancers.

Shares of GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) have earned a consensus recommendation of "Hold" from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $119.80.

A number of analysts have commented on the stock. Guggenheim increased their price objective on shares of GRAIL from $75.00 to $155.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Canaccord Genuity Group boosted their target price on GRAIL from $80.00 to $150.00 and gave the stock a "buy" rating in a report on Monday, September 28th. UBS Group upped their price target on GRAIL from $105.00 to $175.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. Royal Bank Of Canada began coverage on GRAIL in a research report on Thursday, September 17th. They set a "sector perform" rating and a $84.00 price objective on the stock. Finally, Wall Street Zen raised GRAIL from a "sell" rating to a "hold" rating in a research note on Sunday, September 13th.

GRAIL Stock Up 5.6%

Shares of GRAIL stock opened at $139.91 on Tuesday. The firm has a market cap of $6.25 billion, a PE ratio of -14.35 and a beta of 2.83. GRAIL has a twelve month low of $41.50 and a twelve month high of $166.48. The business has a 50-day moving average price of $104.22 and a 200 day moving average price of $77.36.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating analysts' consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, sell-side analysts expect that GRAIL will post -10.07 EPS for the current year.

Insider Activity at GRAIL

In related news, CEO Joshua J. Ofman sold 20,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $136.85, for a total transaction of $2,737,000.00. Following the completion of the sale, the chief executive officer directly owned 342,271 shares of the company's stock, valued at approximately $46,839,786.35. This trade represents a 5.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 23,619 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the transaction, the chief financial officer directly owned 225,364 shares in the company, valued at approximately $32,991,035.96. The trade was a 9.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 129,944 shares of company stock valued at $14,832,805. 1.83% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Apollon Wealth Management LLC acquired a new position in GRAIL during the third quarter worth $226,000. Slow Capital Inc. raised its stake in shares of GRAIL by 0.5% during the 3rd quarter. Slow Capital Inc. now owns 218,363 shares of the company's stock worth $30,597,000 after buying an additional 1,101 shares during the last quarter. Root Financial Partners LLC purchased a new stake in shares of GRAIL in the 3rd quarter worth about $44,000. SBI Securities Co. Ltd. boosted its position in shares of GRAIL by 110.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 388 shares of the company's stock worth $54,000 after buying an additional 204 shares in the last quarter. Finally, Pinnacle Associates Ltd. purchased a new stake in shares of GRAIL in the 3rd quarter worth about $208,000.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.